126 related articles for article (PubMed ID: 37303241)
1. The American Society of Clinical Oncology-College of American Pathologists Guideline Update for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer.
Schnitt SJ; Tarantino P; Collins LC
Arch Pathol Lab Med; 2023 Sep; 147(9):991-992. PubMed ID: 37303241
[No Abstract] [Full Text] [Related]
2. Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer.
Shah SS; Ketterling RP; Goetz MP; Ingle JN; Reynolds CA; Perez EA; Chen B
Hum Pathol; 2010 Jan; 41(1):103-6. PubMed ID: 19762065
[TBL] [Abstract][Full Text] [Related]
3. American Society of Clinical Oncology/College of American Pathologists Human Epidermal Growth Factor Receptor 2 Testing Clinical Practice Guideline Upcoming Modifications: Proof That Clinical Practice Guidelines Are Living Documents.
Hammond ME; Hicks DG
Arch Pathol Lab Med; 2015 Aug; 139(8):970-1. PubMed ID: 25884371
[No Abstract] [Full Text] [Related]
4. Impact of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Updates on HER2 Assessment in Breast Cancer With Equivocal HER2 Immunohistochemistry Results With Focus on Cases With
Hoda RS; Brogi E; Xu J; Ventura K; Ross DS; Dang C; Robson M; Norton L; Morrow M; Wen HY
Arch Pathol Lab Med; 2020 May; 144(5):597-601. PubMed ID: 31647316
[TBL] [Abstract][Full Text] [Related]
5. National guidelines and level of evidence: comments on some of the new recommendations in the American Society of Clinical Oncology and the College of American Pathologists human epidermal growth factor receptor 2 guidelines for breast cancer.
Rakha EA; Pigera M; Shaaban A; Shin SJ; D'Alfonso T; Ellis IO; Lee AH
J Clin Oncol; 2015 Apr; 33(11):1301-2. PubMed ID: 25753440
[No Abstract] [Full Text] [Related]
6. Impact of the updated 2018 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines on Human Epidermal Growth Factor Receptor 2 (HER2) gene testing in invasive breast cancers: A single center study.
Lim TH; Lim AST; Tien SL; Tan PH
Ann Diagn Pathol; 2022 Jun; 58():151935. PubMed ID: 35313158
[TBL] [Abstract][Full Text] [Related]
7. Next-generation assessment of human epidermal growth factor receptor 2 gene (ERBB2) amplification status in invasive breast carcinoma: a focus on Group 4 by use of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 testing guideline.
Hoda RS; Bowman AS; Zehir A; Razavi P; Brogi E; Ladanyi M; Arcila ME; Wen HY; Ross DS
Histopathology; 2021 Mar; 78(4):498-507. PubMed ID: 32841416
[TBL] [Abstract][Full Text] [Related]
8. Clinical and Pathologic Features Associated With Invasive Breast Carcinoma With 2018 American Society of Clinical Oncology/College of American Pathologists In Situ Hybridization Group 2 Results (Human Epidermal Growth Factor Receptor 2 [HER2]/Chromosome 17 Centromere [CEP17] Ratio ≥2.0 and Average HER2 Copy Number <4.0).
Hoda RS; Zarei S; McIntire PJ; Sprague C; Mekhail Y; Carlson DL; Komforti MK; Downs-Kelly EP
Arch Pathol Lab Med; 2022 Jun; 146(6):701-709. PubMed ID: 34559875
[TBL] [Abstract][Full Text] [Related]
9. Impact of the Updated 2018 American Society of Clinical Oncology/College of American Pathologists Guideline for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer.
Li A; Bai Q; Kong H; Zhou S; Lv H; Zhong S; Li M; Bi R; Zhou X; Yang W
Arch Pathol Lab Med; 2020 Sep; 144(9):1097-1107. PubMed ID: 32142367
[TBL] [Abstract][Full Text] [Related]
10. Human Epidermal Growth Factor Receptor 2 Testing by Fluorescent In Situ Hybridization: Positive or Negative? American Society of Clinical Oncology/College of American Pathologists Guidelines 2007, 2013, and 2018.
Murray C; D'Arcy C; Gullo G; Flanagan L; Quinn CM
Arch Pathol Lab Med; 2019 Apr; 143(4):412-413. PubMed ID: 30605368
[No Abstract] [Full Text] [Related]
11. Impact of the 2013 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing of invasive breast carcinoma: a focus on tumours assessed as 'equivocal' for HER2 gene amplification by fluorescence in-situ hybridization.
Bethune GC; Veldhuijzen van Zanten D; MacIntosh RF; Rayson D; Younis T; Thompson K; Barnes PJ
Histopathology; 2015 Dec; 67(6):880-7. PubMed ID: 25913507
[TBL] [Abstract][Full Text] [Related]
12. Implementation of the 2018 Human Epidermal Growth Factor Receptor 2 Guideline by American Society of Clinical Oncology/College of American Pathologists Will Reduce False-Positive Tests.
Martin V; Valera A; De Joffrey M; Banfi S; Mazzucchelli L
Arch Pathol Lab Med; 2019 Apr; 143(4):411-412. PubMed ID: 30605369
[No Abstract] [Full Text] [Related]
13. HER2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update Summary.
Wolff AC; Hammond MEH; Allison KH; Harvey BE; McShane LM; Dowsett M
J Oncol Pract; 2018 Jul; 14(7):437-441. PubMed ID: 29920138
[No Abstract] [Full Text] [Related]
14. 2013 update of the American Society of Clinical Oncology/College of American Pathologists guideline for human epidermal growth factor receptor 2 testing: impact on immunohistochemistry-negative breast cancers.
Lambein K; Van Bockstal M; Denys H; Libbrecht L
J Clin Oncol; 2014 Jun; 32(17):1856-7. PubMed ID: 24778399
[No Abstract] [Full Text] [Related]
15. Quantitative Impact of the 2018 American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) Practice Guideline Update on Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: A Systematic Analysis.
Wei CH; Garcia L; Murata-Collins J; Schmolze D; Apple S
Arch Pathol Lab Med; 2021 Jul; 145(7):887-890. PubMed ID: 33112946
[TBL] [Abstract][Full Text] [Related]
16. American Society of Clinical Oncology/College of American Pathologists 2018 Focused Update of Breast Cancer HER2 FISH Testing GuidelinesResults From a National Reference Laboratory.
Lin L; Sirohi D; Coleman JF; Gulbahce HE
Am J Clin Pathol; 2019 Sep; 152(4):479-485. PubMed ID: 31172196
[TBL] [Abstract][Full Text] [Related]
17. The updated 2018 American Society of Clinical Oncology/College of American Pathologists guideline on human epidermal growth factor receptor 2 interpretation in breast cancer: comparison with previous guidelines and clinical significance of the proposed in situ hybridization groups.
Woo JW; Lee K; Chung YR; Jang MH; Ahn S; Park SY
Hum Pathol; 2020 Apr; 98():10-21. PubMed ID: 32027910
[TBL] [Abstract][Full Text] [Related]
18. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer.
Wolff AC; Somerfield MR; Dowsett M; Hammond MEH; Hayes DF; McShane LM; Saphner TJ; Spears PA; Allison KH
Arch Pathol Lab Med; 2023 Sep; 147(9):993-1000. PubMed ID: 37303228
[TBL] [Abstract][Full Text] [Related]
19. ASCO-CAP guidelines for breast predictive factor testing: an update.
Hammond ME
Appl Immunohistochem Mol Morphol; 2011 Dec; 19(6):499-500. PubMed ID: 22089488
[TBL] [Abstract][Full Text] [Related]
20. Laboratory compliance with the American Society of Clinical Oncology/college of American Pathologists guidelines for human epidermal growth factor receptor 2 testing: a College of American Pathologists survey of 757 laboratories.
Nakhleh RE; Grimm EE; Idowu MO; Souers RJ; Fitzgibbons PL
Arch Pathol Lab Med; 2010 May; 134(5):728-34. PubMed ID: 20441503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
